Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder
Portfolio Pulse from Vandana Singh
Regeneron Pharmaceuticals Inc and Sanofi SA announced positive results from the second Phase 3 trial (NOTUS) of Dupixent for treating COPD, showing significant reduction in exacerbations and improvements in lung function. The EMA is reviewing Dupixent for COPD, and the companies plan to submit trial data to the FDA by year-end. Interim analysis results will be the primary analysis for the trial. Sanofi also plans to spin off its consumer healthcare business to focus on innovative medicines and vaccines. REGN shares closed at $798.30, and SNY stock is up 0.89% at $47.60 in premarket trading.
November 27, 2023 | 2:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Dupixent shows promise in a second Phase 3 COPD trial, potentially strengthening its product portfolio and market position.
Positive trial results typically lead to increased investor confidence in a drug's potential, which can drive up the stock price. The successful NOTUS trial and planned FDA submission are likely to be viewed favorably by investors.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Sanofi's collaboration with Regeneron on Dupixent continues to yield positive results, which may positively impact its stock price and strategic focus on innovative medicines.
The positive outcome of the NOTUS trial for Dupixent, which Sanofi co-develops with Regeneron, is likely to be seen as a strong indicator of the drug's commercial potential, supporting Sanofi's stock price and its strategic shift towards innovative medicines.
CONFIDENCE 80
IMPORTANCE 80
RELEVANCE 90